International literature reports a case of effective short‐term treatment with injectable Semaglutide 0.25–0.5 mg weekly in a 27‐year woman with class I obesity (BMI 30 kg/m2) and T1D, poor glucose control (HbA1c 12.9%), suboptimal adherence to insulin prescription, and binge eating with overnight eating. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.